Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2017 09:00 ET | Source: TESARO, Inc.

TESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England

WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D.,...
June 26, 2017 16:15 ET | Source: TESARO, Inc.

TESARO Joins Healthcare Businesswomen’s Association as Corporate Partner

WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Healthcare Businesswomen’s Association (HBA) as a...
June 07, 2017 16:30 ET | Source: TESARO, Inc.

TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference

WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global...
June 03, 2017 18:30 ET | Source: TESARO, Inc.

TESARO Provides Business and Pipeline Update at ASCO Investor Briefing

Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1...
May 25, 2017 16:15 ET | Source: TESARO, Inc.

Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...
May 22, 2017 09:01 ET | Source: TESARO, Inc.

National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community

WALTHAM, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the results of the Our Way Forward survey – a national...
May 11, 2017 02:01 ET | Source: TESARO, Inc.

TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer

WALTHAM, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- TESARO Inc. (NASDAQ:TSRO) and Clinigen Group plc’s (AIM:CLIN) ('Clinigen') Idis Managed Access division have partnered to launch a Managed Access...
May 09, 2017 16:05 ET | Source: TESARO, Inc.

TESARO Announces First-Quarter 2017 Operating Results

ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical...
May 01, 2017 08:30 ET | Source: TESARO, Inc.

TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA

WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...
April 27, 2017 08:15 ET | Source: TESARO, Inc.

TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042

TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right